Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
Western Alliance Q2 FY26 net income climbs 13.03% to $268.8 million; revenue rises 17.71% to $995.7 million

Western Alliance Q2 FY26 net income climbs 13.03% to $268.8 million; revenue rises 17.71% to $995.7 million

ReutersReuters2026/07/31 20:22
  • Western Alliance posted Q2 net income available to common stockholders of $258.5 million, up 13.78% year over year; diluted EPS rose 14.01% to $2.36.
  • Net revenue climbed 17.71% to $995.7 million, while net interest margin was unchanged at 3.53%.
  • Provision for credit losses jumped to $80.4 million from $39.9 million a year earlier; annualized net loan charge-offs rose to 0.37% from 0.22%.
  • Nonperforming loans to funded held-for-investment loans increased to 0.92% from 0.85% at Dec. 31, 2025; total deposits rose 6.1% to $81.9 billion.
  • Management launched a deposit optimization strategy in Q2 to reduce higher-cost balances, cutting more than $1 billion of higher-cost deposits near quarter-end.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Western Alliance Bancorporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-26-051418), on July 31, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Competition in US oral weight-loss drugs intensifies! Eli Lilly (LLY.US) Foundayo captures 30% of new patients, narrowing Novo Nordisk's (NVO.US) first-mover advantage

Eli Lilly stated on Monday that its oral weight-loss drug, Foundayo, has captured over 30% of the market share among new patients in the US oral obesity treatment market, narrowing the early lead achieved by Danish competitor Novo Nordisk with its Wegovy oral tablets.

智通财经2026/09/15 03:21
Competition in US oral weight-loss drugs intensifies! Eli Lilly (LLY.US) Foundayo captures 30% of new patients, narrowing Novo Nordisk's (NVO.US) first-mover advantage